The innovation nodes in the Stockholm region are key platforms for collaboration that bridge gaps in innovation ecosystems. Additional resources are now needed to strengthen inter-nodal co-operation.
A Working Lab (AWL) Innomedicum on Solna Campus is home to start-ups in life science, offering office space and lab facilities to new companies. We had the chance to speak to Åsa Johansson, newly appointed head of A Working Lab, Akademiska Hus, to find out more.
Karolinska Cell Therapy Center (KCC) is a core facility whose function is to facilitate the development of new treatments with advanced therapy drugs (ATMP) and cells for transplant. Pontus Blomberg, operations manager at KCC, tells us more!
STARTUP is a competition for startups with a clear connection to Flemingsberg, either as students, residents or otherwise active in the area. In addition to the prize money of SEK 10,000, the winner will also have a free place for three months in Flemingsbergs Sciences' innovation environment. Deadline for participation is April 5.
Campus Flemingsberg now has its very own campus choir: Flemingos. During the autumn, three students at the Stockholm University College of Music Education, (SMI), led a group of around ten singers. Next semester, the choir will get back together again, when they will be joined by a chamber choir.
The Center for Bioinformatics and Biostatistics (CBB) provides support and knowledge on bioinformatics and biostatistics research methods. The goal is to improve opportunities for researchers at Campus Flemingsberg to use new research methods and provide training in existing methods.
The idea behind HappyPaws is an open platform that provides pet owners power over their pets’ medical records. It would give pet owners a better overview of their animals’ medical histories, from previous visits to the vet to the vaccination status, and allow information to be shared with other users.
Invest Stockholm has now updated its presentation of the region's research and the companies working with neurodegenerative diseases. Here you will find, among others, AlzeCure, which is developing a painkiller based on this year's Nobel Prize in Medicine.
“We’re developing a completely new drug to combat viral infections – an antiviral drug – using modern genetic engineering. Our methods are based on the Nobel-winning CRISPR technology that paves the way to new, targeted treatments,” says Theodor Pramer, CEO of Biomedrex Genetics.
Johnny Högberg is the new CEO of Flemingsberg Science. His objectives include attracting more companies to the area and strengthening Flemingsberg’s existing innovation support system.